Biotech RadarJobs updated

COMPANY

Crossbow Therapeutics

HQ: Cambridge, MA source · crossbowtx.com ↗

Clinical Phase 1

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Recurrent or Progressive Glioblastoma Relapse or Refractory Myeloid Malignancies High-risk Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia AML - Acute Myeloid Leukemia Chronic Myeloid Leukemia CBX-663 CBX-250

2Trials (company is sponsor)

Timeline

  1. Trial start 1: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumo source ↗
  2. Trial start Phase 1: A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT07779798A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.1Not yet recruiting2026-082028-01 (estimated)
NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasPhase 1RecruitingJul 16, 20252027-01 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback